TG Therapeutics, Inc. (FRA:NKB2)
Germany · Delayed Price · Currency is EUR 28.53
-0.73 (-2.48%)
At close: Nov 28, 2025
TG Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 531.9 | 329 | 233.66 | 2.79 | 6.69 | 0.15 | Upgrade | |
Revenue Growth (YoY) | 100.88% | 40.80% | 8290.02% | -58.36% | 4300.66% | - | Upgrade |
Cost of Revenue | 77.97 | 38.49 | 14.13 | 0.27 | 0.79 | - | Upgrade |
Gross Profit | 453.93 | 290.52 | 219.53 | 2.52 | 5.9 | 0.15 | Upgrade |
Selling, General & Admin | 208.25 | 154.3 | 122.71 | 95.48 | 128.09 | 107.85 | Upgrade |
Research & Development | 142.9 | 94.29 | 76.19 | 125.35 | 222.58 | 165.9 | Upgrade |
Operating Expenses | 351.15 | 248.59 | 198.9 | 220.84 | 350.67 | 273.75 | Upgrade |
Operating Income | 102.78 | 41.93 | 20.63 | -218.32 | -344.77 | -273.59 | Upgrade |
Interest Expense | -27.26 | -24.03 | -12.62 | -10.19 | -5.64 | -6.33 | Upgrade |
Other Non Operating Income (Expenses) | 12.23 | 7.69 | 5.04 | 4.7 | 2.31 | 0.54 | Upgrade |
Pretax Income | 87.75 | 25.59 | 13.06 | -223.81 | -348.1 | -279.38 | Upgrade |
Income Tax Expense | -359.72 | 2.21 | 0.39 | - | - | - | Upgrade |
Net Income | 447.47 | 23.38 | 12.67 | -223.81 | -348.1 | -279.38 | Upgrade |
Net Income to Common | 447.47 | 23.38 | 12.67 | -223.81 | -348.1 | -279.38 | Upgrade |
Net Income Growth | - | 84.52% | - | - | - | - | Upgrade |
Shares Outstanding (Basic) | 146 | 145 | 142 | 135 | 132 | 115 | Upgrade |
Shares Outstanding (Diluted) | 162 | 160 | 149 | 135 | 132 | 115 | Upgrade |
Shares Change (YoY) | 11.64% | 7.96% | 9.67% | 2.41% | 14.64% | 30.51% | Upgrade |
EPS (Basic) | 3.06 | 0.16 | 0.09 | -1.65 | -2.63 | -2.42 | Upgrade |
EPS (Diluted) | 2.78 | 0.15 | 0.09 | -1.65 | -2.63 | -2.42 | Upgrade |
EPS Growth | - | 68.03% | - | - | - | - | Upgrade |
Free Cash Flow | -70.24 | -40.56 | -31.41 | -176.18 | -296.04 | -214.86 | Upgrade |
Free Cash Flow Per Share | -0.43 | -0.25 | -0.21 | -1.30 | -2.24 | -1.86 | Upgrade |
Gross Margin | 85.34% | 88.30% | 93.95% | 90.48% | 88.19% | 100.00% | Upgrade |
Operating Margin | 19.32% | 12.74% | 8.83% | -7838.99% | -5154.28% | -179996.05% | Upgrade |
Profit Margin | 84.13% | 7.11% | 5.42% | -8036.34% | -5204.08% | -183803.29% | Upgrade |
Free Cash Flow Margin | -13.21% | -12.33% | -13.44% | -6326.18% | -4425.70% | -141357.90% | Upgrade |
EBITDA | 102.83 | 42 | 20.84 | -218.01 | -344.49 | -273.44 | Upgrade |
EBITDA Margin | 19.33% | 12.77% | 8.92% | - | - | - | Upgrade |
D&A For EBITDA | 0.05 | 0.07 | 0.21 | 0.3 | 0.28 | 0.16 | Upgrade |
EBIT | 102.78 | 41.93 | 20.63 | -218.32 | -344.77 | -273.59 | Upgrade |
EBIT Margin | 19.32% | 12.74% | 8.83% | - | - | - | Upgrade |
Effective Tax Rate | - | 8.64% | 2.99% | - | - | - | Upgrade |
Revenue as Reported | 531.9 | 329 | 233.66 | 2.79 | 6.69 | 0.15 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.